Target Price | €45.38 |
Price | €40.59 |
Potential | 11.79% |
Number of Estimates | 18 |
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €45.38. This is 11.79% higher than the current stock price. The highest price target is €51.20 26.15% , the lowest is €38.88 4.21% . | |
A rating was issued by 24 analysts: 14 Analysts recommend Qiagen to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 11.79% . Most analysts recommend the Qiagen stock at Purchase. |
26 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 3.97% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 8.08% , the lowest is €1.7b 2.21% .
This results in the following potential growth metrics:
2024 | €1.7b | 0.66% |
---|---|---|
2025 | €1.8b | 7.22% |
2026 | €1.9b | 5.66% |
2027 | €2.1b | 6.92% |
2028 | €2.3b | 12.10% |
2029 | €2.5b | 7.26% |
2030 | €2.9b | 16.45% |
24 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €674m . This is 41.72% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €757m 59.11% , the lowest is €590m 24.07% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €432m | 10.64% |
---|---|---|
2025 | €674m | 56.08% |
2026 | €731m | 8.47% |
2027 | €790m | 8.11% |
2028 | €829m | 4.88% |
2029 | €854m | 3.00% |
2024 | 25.51% | 9.92% |
---|---|---|
2025 | 37.13% | 45.58% |
2026 | 38.12% | 2.67% |
2027 | 38.54% | 1.10% |
2028 | 36.06% | 6.43% |
2029 | 34.63% | 3.97% |
27 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €445m . This is 39.20% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €487m 52.44% , the lowest is €421m 31.86% .
This results in the following potential growth metrics and future Net Margins:
2024 | €71.5m | 75.51% |
---|---|---|
2025 | €445m | 521.74% |
2026 | €482m | 8.31% |
2027 | €529m | 9.88% |
2028 | €581m | 9.69% |
2029 | €606m | 4.45% |
2024 | 4.23% | 75.67% |
---|---|---|
2025 | 24.51% | 480.00% |
2026 | 25.12% | 2.49% |
2027 | 25.82% | 2.79% |
2028 | 25.26% | 2.17% |
2029 | 24.60% | 2.61% |
27 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.05 . This is 41.38% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.25 55.17% , the lowest is €1.94 33.79% .
This results in the following potential growth metrics and future valuations:
2024 | €0.33 | 74.81% |
---|---|---|
2025 | €2.05 | 521.21% |
2026 | €2.22 | 8.29% |
2027 | €2.44 | 9.91% |
2028 | €2.68 | 9.84% |
2029 | €2.80 | 4.48% |
Current | 27.39 | 81.70% |
---|---|---|
2025 | 19.36 | 29.31% |
2026 | 17.87 | 7.70% |
2027 | 16.27 | 8.95% |
2028 | 14.83 | 8.85% |
2029 | 14.20 | 4.25% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.98 and an P/S ratio of 4.75 .
This results in the following potential growth metrics and future valuations:
Current | 5.18 | 8.80% |
---|---|---|
2025 | 4.98 | 3.88% |
2026 | 4.71 | 5.35% |
2027 | 4.41 | 6.47% |
2028 | 3.93 | 10.80% |
2029 | 3.67 | 6.77% |
2030 | 3.15 | 14.13% |
Current | 4.94 | 8.92% |
---|---|---|
2025 | 4.75 | 3.81% |
2026 | 4.49 | 5.35% |
2027 | 4.20 | 6.47% |
2028 | 3.75 | 10.80% |
2029 | 3.50 | 6.77% |
2030 | 3.00 | 14.13% |
Analyst | Rating | Action | Date |
---|---|---|---|
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Feb 07 2025 |
Analyst Rating | Date |
---|---|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Feb 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.